Biotech firm Moderna recently announced that it would never enforce the patent on its COVID-19 vaccine in 92 countries currently receiving the shots through a global program. It’s the first major pharmaceutical company to announce such a move, which critics say came later than it should have and which opens the door to wide-scale global production. Under CEO Stéphane Bancel, Moderna is also developing mRNA vaccines targeting 15 pathogens that are more common in the developing world, as well as longtime public-health threats such as influenza and RSV.
A weekly newsletter featuring conversations with the world’s top CEOs, managers, and founders. Join the Leadership Brief.
- The Fall of Roe and the Failure of the Feminist Industrial Complex
- What Trump Knew About January 6
- Follow the Algae Brick Road to Plant-Based Buildings
- The Education of Glenn Youngkin
- The Benefits and Challenges of Cutting Back on Meat
- Here's Everything New on Netflix in July 2022—and What's Leaving
- Women in Northern Ireland Still Struggle to Access Abortion More Than 2 Years After Decriminalization